Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2, 2007. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of April 30, 2007, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital: 6,019,155,030 Ordinary shares of 25p each.
- Treasury Shares: 290,182,678 Ordinary shares held in Treasury.
- Total Voting Rights: 5,728,972,352.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. No comparative data from previous periods is included in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share capital figures intended for shareholder calculations under Financial Services Authority rules.
Important Facts for Investors to Verify
- Verify the total number of voting rights (5,728,972,352) to determine notification thresholds under Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (290,182,678) when calculating the denominator for ownership interest.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and earnings metrics.